Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease-Reference-Cited by-同舟云学术

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

Published:2011-03-22 Issue:3 Volume:31 Page:323-331
ISSN:0271-9142
Container-title:Journal of Clinical Immunology
language:en
Short-container-title:J Clin Immunol

Author:

Wasserman Richard L.,Melamed Isaac,Kobrynski Lisa,Strausbaugh Steven D.,Stein Mark R.,Sharkhawy Marlies,Engl Werner,Leibl Heinz,Sobolevsky Luba,Gelmont David,Schiff Richard I.,Grossman William J.

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s10875-011-9512-z.pdf

Reference27 articles.

1. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies. Advantages of the subcutaneous route. Biodrogs. 2007;21(2):105–16.

2. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Björkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94–100.

3. Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2(5):368–78.

4. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.

5. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—A prospective multi-national study. J Clin Immunol. 2006;26:177–85.

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity;Journal of Medical Economics;2024-07

2. Elevated Liver Enzymes With Positive Hepatitis B Serology After Intravenous Immunoglobulin Treatment of Guillain-Barré Syndrome;ACG Case Reports Journal;2023-12

3. Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis;Cancers;2023-09-12

4. Exact sample size determination for a single Poisson random sample;Biometrical Journal;2023-05-09

5. Cost-minimization analysis of HYQVIA® in the treatment of primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID) in Italy;AboutOpen;2023-05-02